Ruxolitinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4000 publications

Immune Checkpoint Inhibitor Myocarditis and Myotoxicity.

Immune Checkpoint Inhibitor Myocarditis and Myotoxicity.

Journal: Circulation
Published: September 08, 2026

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.

Journal: The Journal of dermatological treatment
Published: September 07, 2026

Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis

Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 07, 2026

Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.

Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.

Journal: Hematology (Amsterdam, Netherlands)
Published: September 05, 2026

Second-line and salvage therapies for steroid-refractory acute graft-versus-host disease: an integrated synthesis of current evidence and clinical sequencing.

Second-line and salvage therapies for steroid-refractory acute graft-versus-host disease: an integrated synthesis of current evidence and clinical sequencing.

Journal: Current opinion in hematology
Published: August 31, 2026

Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials.

Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials.

Journal: The Journal of dermatological treatment
Published: August 28, 2026

Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors.

Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors.

Journal: Expert opinion on pharmacotherapy
Published: August 21, 2026

Second corrigendum to Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease.

Second corrigendum to Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease.

Journal: The Journal of clinical investigation
Published: August 17, 2026

Acute erythroid leukaemia transformation in polycythaemia vera with leukemic involvement in liver and ascites.

Acute erythroid leukaemia transformation in polycythaemia vera with leukemic involvement in liver and ascites.

Journal: BMJ case reports
Published: August 03, 2026

A Novel MPIG6B Gene Variant Identified in a Patient with Congenital Thrombocytopenia from Turkey.

A Novel MPIG6B Gene Variant Identified in a Patient with Congenital Thrombocytopenia from Turkey.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology
Published: July 31, 2026

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2026

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences
Published: July 29, 2026
Showing 1-12 of 4,000

Last Updated: 09/26/2026